JP2018527295A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527295A5
JP2018527295A5 JP2017566161A JP2017566161A JP2018527295A5 JP 2018527295 A5 JP2018527295 A5 JP 2018527295A5 JP 2017566161 A JP2017566161 A JP 2017566161A JP 2017566161 A JP2017566161 A JP 2017566161A JP 2018527295 A5 JP2018527295 A5 JP 2018527295A5
Authority
JP
Japan
Prior art keywords
group
ring
atom
substituted
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017566161A
Other languages
English (en)
Japanese (ja)
Other versions
JP6689297B2 (ja
JP2018527295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2016/072244 external-priority patent/WO2017014323A1/en
Publication of JP2018527295A publication Critical patent/JP2018527295A/ja
Publication of JP2018527295A5 publication Critical patent/JP2018527295A5/ja
Application granted granted Critical
Publication of JP6689297B2 publication Critical patent/JP6689297B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017566161A 2015-07-23 2016-07-22 複素環化合物 Expired - Fee Related JP6689297B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2244DE2015 2015-07-23
IN2244/DEL/2015 2015-07-23
PCT/JP2016/072244 WO2017014323A1 (en) 2015-07-23 2016-07-22 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2018527295A JP2018527295A (ja) 2018-09-20
JP2018527295A5 true JP2018527295A5 (OSRAM) 2019-06-13
JP6689297B2 JP6689297B2 (ja) 2020-04-28

Family

ID=56740432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566161A Expired - Fee Related JP6689297B2 (ja) 2015-07-23 2016-07-22 複素環化合物

Country Status (7)

Country Link
US (2) US10745397B2 (OSRAM)
EP (1) EP3325490B1 (OSRAM)
JP (1) JP6689297B2 (OSRAM)
CN (1) CN108368127B (OSRAM)
CA (1) CA2993312A1 (OSRAM)
DK (1) DK3325490T3 (OSRAM)
WO (1) WO2017014323A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PT3625228T (pt) 2017-05-18 2021-09-16 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores dos recetores de pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
LT3625224T (lt) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd N-pakeistieji indolo dariniai
LT3625222T (lt) 2017-05-18 2021-11-10 Idorsia Pharmaceuticals Ltd Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
WO2019147987A1 (en) * 2018-01-26 2019-08-01 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Antimicrobial compositions and methods of using the same
EP3749323A4 (en) * 2018-02-05 2021-11-03 Shenzhen Ionova Life Science Co., Ltd. HETEROBICYCLIC CARBOXYLIC ACIDS TO TREAT CANCER OR INFLAMMATORY DISEASES
UA127747C2 (uk) 2018-10-23 2023-12-20 Басф Се Трициклічні пестицидні сполуки
KR20210146288A (ko) * 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로사이클릴 화합물 및 이의 용도
CN112094249B (zh) * 2019-06-17 2022-03-08 中国科学院苏州纳米技术与纳米仿生研究所 磺胺甲噻二唑-糖精共晶及其制备方法与应用
EP4620531A3 (en) 2019-11-08 2025-11-26 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP4136086A1 (en) 2020-04-14 2023-02-22 Basf Se Tricyclic pesticidal compounds
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
JPWO2022102731A1 (OSRAM) 2020-11-13 2022-05-19

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752421B1 (en) * 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
KR20220084426A (ko) 2004-07-28 2022-06-21 다케다 야쿠힌 고교 가부시키가이샤 피롤로〔2,3-c〕피리딘 화합물, 그 제조 방법 및 용도
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
CA2682162C (en) * 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
SI2565191T1 (sl) * 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US8404736B2 (en) * 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
WO2010080864A1 (en) 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
PT2619182T (pt) 2010-09-21 2017-01-17 Eisai R&D Man Co Ltd Composição farmacêutica
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016088903A1 (en) 2014-12-05 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds

Similar Documents

Publication Publication Date Title
JP2018527295A5 (OSRAM)
JP2016531950A5 (ja) 複素環化合物
JP2016516043A5 (OSRAM)
JP2013510125A5 (OSRAM)
JP2017502940A5 (OSRAM)
JP2015522650A5 (OSRAM)
JP2015517976A5 (OSRAM)
JP2014514360A5 (OSRAM)
JP2016540742A5 (OSRAM)
JP2014525438A5 (OSRAM)
JP2017525668A5 (OSRAM)
JP2013528204A5 (OSRAM)
JP2013502431A5 (OSRAM)
JP2016516699A5 (OSRAM)
PE20090596A1 (es) Imidazoles biciclicos fusionados
JP2014500295A5 (OSRAM)
RU2015106434A (ru) Производные типа азаиндазола или диазаиндазола для лечения боли
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2017509689A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2016513696A5 (OSRAM)
JP2015504076A5 (OSRAM)
JP2014509600A5 (OSRAM)
AR107633A1 (es) Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
JP2016513681A5 (OSRAM)